Compare GNLX & IPEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | IPEX |
|---|---|---|
| Founded | 2001 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.0M | 125.5M |
| IPO Year | 2022 | N/A |
| Metric | GNLX | IPEX |
|---|---|---|
| Price | $3.01 | $10.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 145.4K | 41.8K |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $41.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.29 | $10.25 |
| 52 Week High | $8.54 | $10.56 |
| Indicator | GNLX | IPEX |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 64.04 |
| Support Level | $2.74 | $10.42 |
| Resistance Level | $2.98 | N/A |
| Average True Range (ATR) | 0.12 | 0.01 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 20.75 | 80.00 |
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Inflection Point Acquisition Corp V is a blank check company.